Recent Updates — OGN

Organon & Co. filed a Form 10-Q for the quarter ended September 30, 2026, furnishing supplemental non-GAAP financial metrics in lieu of its customary earnings press release due to its pending merger with Sun Pharmaceutical Industries Limited. The company reported GAAP diluted earnings per share of $0.60 and net income of $164 million for the quarter. Adjusted metrics included adjusted net income of $256 million, adjusted diluted EPS of $0.94, and adjusted EBITDA of $502 million. For the nine-month period, GAAP diluted EPS was $1.56 with net income of $418 million, while adjusted diluted EPS stood at $2.51 and adjusted EBITDA reached $1.378 billion. Organon & Co. operates in the pharmaceutical industry.

Organon & Co. filed a Form 8-K on July 31, 2026, to furnish supplemental non-GAAP financial metrics for the quarter ended June 30, 2026, in lieu of a standard earnings press release due to its pending merger with Sun Pharmaceutical Industries Limited. The company reported Adjusted EBITDA of $461 million and Adjusted Net Income of $230 million for the three-month period. GAAP diluted EPS was $0.40 compared to an Adjusted Diluted EPS of $0.85. Organon & Co. operates in the pharmaceutical industry, focusing on consumer health and specialty medicines.

On July 23, 2026, Organon & Co. stockholders approved a merger agreement dated April 26, 2026, with Sun Pharmaceutical Holdings USA, Inc. Under the terms, Sun Pharma America, Inc. will merge into Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. Stockholders also approved, on a non-binding advisory basis, the merger-related compensation for named executive officers. The merger proposal passed with 192,776,552 votes in favor and 2,573,118 against. Organon & Co. operates in the healthcare industry and develops and manufactures medicines and vaccines for women's health.

Organon & Co. is voluntarily supplementing its Definitive Proxy Statement following a lawsuit filed in New Jersey alleging that merger disclosures were materially incomplete and misleading. The supplement includes updated synergy estimates of approximately $700 million and financial projections for revenue and Adjusted EBITDA through 2030. Organon & Co. is a pharmaceutical company specializing in women's health and established brands.

At its 2026 Annual Meeting held on June 9, 2026, Organon & Co. stockholders approved an amendment and restatement of the 2021 Incentive Stock Plan, which increases the number of common shares available for issuance by 8,000,000. Shareholders also elected ten directors to serve until the 2027 annual meeting, approved executive compensation on a non-binding advisory basis, and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year. The meeting saw approximately 77% of outstanding shares represented. Organon & Co. is a pharmaceutical company.